NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
Clinical Trials
154 trialsNCT04398680 2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1 Withdrawn
NCT07150767 2025-12-02
A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1 Withdrawn
NCT05634954 2025-10-23
Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer
GE Healthcare
Phase 1 Withdrawn
NCT05263739 2025-09-12
A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies
Shanghai Escugen Biotechnology Co., Ltd
Phase 1 Withdrawn
NCT05983146 2025-07-24
Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Withdrawn
NCT06235541 2025-07-17
A First-in-human Study of GENA-104A16 in Patients With Advanced Solid Tumors
Genome & Company
Phase 1 Withdrawn
NCT05521087 2025-06-22
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT06719973 2025-06-17
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
EMD Serono
Phase 1 Withdrawn
NCT06816017 2025-06-16
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Hoffmann-La Roche
Phase 1 Withdrawn
NCT06429800 2025-04-24
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
Atara Biotherapeutics
Phase 1 Withdrawn
NCT05940844 2025-04-09
Study of OB-002 in Patients With Refractory Metastatic Cancer
Orion Biotechnology Polska Sp. z o.o.
Phase 1 Withdrawn
NCT05828303 2025-04-01
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT04958967 2025-03-14
Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
Allist Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT04052061 2025-02-21
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
Phase 1 Withdrawn
NCT02743546 2025-02-03
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Phase 1 Withdrawn
NCT06341647 2025-01-24
Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
GC Cell Corporation
Phase 1 Withdrawn
NCT06681870 2025-01-15
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Astellas Pharma Inc
Phase 1 Withdrawn
NCT06372574 2024-09-03
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
Genentech, Inc.
Phase 1 Withdrawn
NCT05622591 2024-08-07
Pediatric AML
Elucida Oncology
Phase 1 Withdrawn
NCT01596413 2024-07-26
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
Kyowa Kirin Co., Ltd.
Phase 1 Withdrawn
NCT01596426 2024-07-26
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
Kyowa Kirin Co., Ltd.
Phase 1 Withdrawn
NCT05039931 2024-07-18
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Withdrawn
NCT05082493 2024-06-06
A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
WPD Pharmaceuticals Sp. z o.o.
Phase 1 Withdrawn
NCT05678283 2024-04-17
A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT05304663 2024-04-08
GLIOASTRA
Philogen S.p.A.
Phase 1 Withdrawn
NCT06219499 2024-04-03
Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841
OncoC4, Inc.
Phase 1 Withdrawn
NCT05472506 2024-03-15
Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer
Ikena Oncology
Phase 1 Withdrawn
NCT02864784 2024-02-28
Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC
Amorphical Ltd.
Phase 1 Withdrawn
NCT05099536 2024-01-31
3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
3D Medicines
Phase 1 Withdrawn
NCT06165809 2023-12-29
A Clinical Trial of TQB3015 Tablets in Patients With Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Withdrawn
NCT05644626 2023-11-29
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
BeiGene
Phase 1 Withdrawn
NCT05259813 2023-11-24
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Withdrawn
NCT05905341 2023-11-08
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT05600582 2023-10-18
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Codagenix, Inc
Phase 1 Withdrawn
NCT05867030 2023-10-17
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Withdrawn
NCT05456269 2023-10-03
BISECT
Race Oncology Ltd
Phase 1 Withdrawn
NCT05828277 2023-09-26
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
Turning Point Therapeutics, Inc.
Phase 1 Withdrawn
NCT05070104 2023-09-13
CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
Cornerstone Pharmaceuticals
Phase 1 Withdrawn
NCT05043987 2023-09-07
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers
Conjupro Biotherapeutics, Inc.
Phase 1 Withdrawn
NCT05245916 2023-09-05
IBI397 or Combination Therapies in Patients With Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Withdrawn
NCT05918250 2023-08-18
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
ModernaTX, Inc.
Phase 1 Withdrawn
NCT05934097 2023-07-06
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Fate Therapeutics
Phase 1 Withdrawn
NCT04896112 2023-06-18
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Lynk Pharmaceuticals Co., Ltd
Phase 1 Withdrawn
NCT03097796 2023-04-27
A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients
Pulmotect, Inc.
Phase 1 Withdrawn
NCT04252768 2023-03-22
AIPAC-002
Immutep S.A.S.
Phase 1 Withdrawn
NCT05259397 2023-03-08
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Pfizer
Phase 1 Withdrawn
NCT05693090 2023-03-06
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Kura Oncology, Inc.
Phase 1 Withdrawn
NCT04759846 2023-02-21
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Pierre Fabre Medicament
Phase 1 Withdrawn
NCT05176691 2023-02-21
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Hutchmed
Phase 1 Withdrawn